CYP19A1 and breast carcinoma: Postmenopausal women diagnosed with estrogen-receptor-positive (ER+) breast cancer are candidates for treatment with aromatase inhibitors (AI) such as letrozole or antiestrogens such as tamoxifen or fulvestrant.